site logo
subscriber logo
X
x
Scrabbl
Think beyond ordinary
Subscribe to our newsletter to explore all the corners of worldly happenings

Channel

Your Details

News

Two of AstraZeneca’s Best-Selling Medicines Show Advances in Deadly Ailments

Imfinzi, a cancer drug, won approval from the U.S. Food and Drug Administration to treat extensive-stage small cell lung cancer, one of the most deadly forms of lung cancer.

Two of AstraZeneca’s Best-Selling Medicines Show Advances in Deadly Ailments
  • Imfinzi is one of a number of new products that have made AstraZeneca into a redoubt of cancer treatments

Two of AstraZeneca Plc’s best-selling medicines showed advances in lethal diseases.

Imfinzi, a cancer drug, won approval from the U.S. Food and Drug Administration to treat extensive-stage small cell lung cancer, one of the most deadly forms of lung cancer.

Imfinzi is one of a number of new products that have made AstraZeneca into a redoubt of cancer treatments -- challenging established rivals like Roche Holding AG -- and sent the shares rising almost 40% in the past two years.

The U.K. drugmaker also said its diabetes drug Farxiga showed “overwhelming efficacy" earlier than expected in a clinical trial on patients with chronic kidney disease, leading Astra to stop it early.

(Except for the headline, this story has not been edited by Scrabbl staff and is published from a syndicated feed.) 


Get our hottest stories delivered to your inbox.

Sign up for Scrabbl Newsletters to get personalized updates on top stories and viral hits.